J 2020

Role of Metoprolol Succinate in the Treatment of Heart Failure and Atrial Fibrillation: A Systematic Review

VINEREANU, Dragos, Jindřich ŠPINAR, Atul PATHAK and Dariusz KOZLOWSKI

Basic information

Original name

Role of Metoprolol Succinate in the Treatment of Heart Failure and Atrial Fibrillation: A Systematic Review

Authors

VINEREANU, Dragos (642 Romania, guarantor), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), Atul PATHAK (250 France) and Dariusz KOZLOWSKI (616 Poland)

Edition

AMERICAN JOURNAL OF THERAPEUTICS, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2020, 1075-2765

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.688

RIV identification code

RIV/00216224:14110/20:00116024

Organization unit

Faculty of Medicine

DOI

UT WoS

000524232900007

Keywords in English

metoprolol; beta-blockers; heart failure; atrial fibrillation

Tags

Tags

International impact, Reviewed
Změněno: 17/7/2020 09:34, Mgr. Tereza Miškechová

Abstract

V originále

Background: Beta-blockers are one of the most important classes of cardiovascular agents and have been considered a cornerstone therapy in heart diseases, such as heart failure (HF) and atrial fibrillation (AF). Among different beta-blockers, metoprolol is a selective beta(1)-adrenergic antagonist, which has been extensively used since the 1970s. Areas of Uncertainty: Although current guidelines include recommendations for the use of controlled-release metoprolol succinate in specific HF and AF indications, and despite extensive clinical experience with metoprolol, comparative evidence on the use of metoprolol succinate compared with other beta-blockers in these indications is limited. Data Sources: We systematically reviewed the data from head-to-head studies directly comparing this compound with other beta-blockers in the treatment of HF or AF. Only clinical trials and observational studies were considered; no other limits were applied. The quality and relevance of retrieved articles were reviewed. Results: A total of 18 articles of the 353 articles identified were selected for inclusion; 12 HF articles and 6 for AF. Additional references were identified from the bibliographies of retrieved articles. The studies show that oral prophylaxis with an appropriate dose of metoprolol may reduce new incidents of AF in high-risk patients. Furthermore, metoprolol succinate is associated with significant mortality and morbidity benefits in the treatment of HF. Conclusions: Despite the introduction of newer beta-blockers with differing clinical characteristics since its introduction, metoprolol succinate remains a useful drug in both HF and AF.